ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
A novel immunoglobulin G- and immunoglobulin cleaving enzyme MG (IceMG), for antibody-mediated rejection.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Profiling Allogeneic HLA-specific B-cell Responses Utilizing a 64-plex Single-HLA Reporter Cell Panel.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Antibody-mediated rejection remains a significant barrier to successful outcomes in both allotransplantation and xenotransplantation. In this study, we investigate the efficacy of a novel recombinant endopeptidase, IceMG, which simultaneously cleaves immunoglobulin (Ig)G) and IgM in rhesus macaques sensitized by sequential skin transplantations. A single intravenous dose of IceMG (2 mg/kg) induced a significant but transient reduction in total IgG and IgM levels. Alloreactive and xenoreactive IgG and IgM, measured by T cell and B cell flow crossmatch assays, also reduced significantly but returned to baseline within 2 weeks. Using a pathogen-specific multiplexed reporter cell panel, nonhuman primates showed a reduction in IgG and IgM responses against severe acute respiratory syndrome coronavirus 2 antigens, including the spike protein, RBD-SD1, and S2 domain antigens, following IceMG treatment. Repeated IceMG treatment produced consistent depletion and reconstitution of IgG and IgM kinetics. IceMG also led to a significant yet temporary decrease in IgM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.